- Report
- January 2024
- 138 Pages
United States
€3627EUR$3,800USD£3,039GBP
- Report
- January 2024
- 113 Pages
United States
€3340EUR$3,500USD£2,799GBP
- Report
- March 2023
- 30 Pages
Global
€11691EUR$12,250USD£9,796GBP
- Report
- February 2023
- 27 Pages
Global
€11691EUR$12,250USD£9,796GBP
- Report
- January 2023
- 31 Pages
Global
€11691EUR$12,250USD£9,796GBP
- Report
- April 2018
United States
From €7630EUR$7,995USD£6,393GBP
- Report
- February 2024
- 77 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- October 2024
Global
From €3340EUR$3,500USD£2,799GBP
- Report
- September 2021
Global
From €4629EUR$4,850USD£3,878GBP
- Report
- January 2025
- 132 Pages
Global
From €907EUR$950USD£760GBP
- Report
- June 2022
- 230 Pages
Global
From €3298EUR$3,456USD£2,764GBP
Ciclosporin is an immunosuppressant drug used to treat a variety of immune disorders, including rheumatoid arthritis, psoriasis, and inflammatory bowel disease. It works by suppressing the body's immune system, which helps to reduce inflammation and prevent organ rejection in transplant patients. It is also used to treat certain types of eye inflammation. Ciclosporin is available in both oral and topical formulations.
Ciclosporin is a widely used drug in the treatment of immune disorders, and is often prescribed in combination with other drugs. It is generally well tolerated, with few side effects. However, it can cause serious side effects, such as high blood pressure, kidney damage, and increased risk of infection.
The ciclosporin market is highly competitive, with many companies offering generic and branded versions of the drug. Some of the major players in the market include Novartis, Pfizer, Merck, and Sanofi. Other companies include Mylan, Teva, and Sandoz. Show Less Read more